Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
37°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vertex Pharmaceuticals Incorporated
< Previous
1
2
3
4
Next >
Vertex Reports Third Quarter 2024 Financial Results
November 04, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in Upcoming November Investor Conferences
October 29, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
October 25, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
October 18, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
October 10, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
September 26, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in Upcoming September Investor Conferences
August 22, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
July 30, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
July 02, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Second Quarter 2024 Financial Results on August 1
July 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
June 21, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
June 14, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
June 07, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in Upcoming June Investor Conferences
May 22, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Jennifer Schneider Elected to Vertex Board of Directors
May 15, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports First Quarter 2024 Financial Results
May 06, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
April 18, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce First Quarter 2024 Financial Results on May 6
April 09, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
April 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 21, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in Upcoming Investor Conferences
February 20, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
February 13, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
February 05, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
February 05, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
January 30, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
January 17, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
January 16, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
January 09, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 07, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.